Probelte Pharma starts a new clinical trial on the safety and efficacy of the subcutaneous Beltavac® Polymerized PRO vaccine for dust mites

In February, Probelte Pharma launched a new clinical trial to assess the efficacy and safety of subcutaneous immunotherapy with a polymerised extract of a mixture of dust mites patients with allergic rhinitis/rhinoconjunctivitis, which will be conducted over one year of treatment and involve 14 centres across the country.

The first volunteers have been recruited, aged between 12 and 65, with the efficacy of Beltavac® Polymerized Pro with dust mite extract being evaluated. The main objective will be to assess the combined nasal symptom and allergy-specific medication score, as well as the patient’s quality of life and asthma control. This evaluation will be completed by the patients on a daily basis via an app, in 4-week periods, repeatedly over the course of a year.

The secondary objective will be to study the safety of the medicine and its impact on health economics during the study period.

Dust mite allergy affects more than 30% of the population in some regions of the country with warm and humid climates. One of the main symptom is rhinitis, which occurs mainly in the morning and at bedtime, and is often accompanied by asthma.

The Beltavac® Polymerized Pro vaccine that is the subject of the trial is composed of a mixture of allergoids from the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae.